Fri, Dec 26, 2014, 12:38 PM EST - U.S. Markets close in 3 hrs 22 mins


% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • sand_snow sand_snow Jan 23, 2014 12:57 PM Flag

    Altogether, these results support evidence that IL-33 acts asa potent adjuvant capable ofinducing and modulating potent Ag-specific cell-mediated immunity in a variety of pathogens.

    Together, these results indicate that the increase in the frequency and
    phenotype of the IL-33-adjuvanted vaccine-induced Ag-specific P14 CD8
    T cells after a prime
    and boost vaccination may be a prediction of the protective correlates ofimmunity behind the
    therapeutic efficacy of immunoadjuvant IL-33 against the established TC-1 tumors (Fig. 6B). We
    are currently investigating the ability of IL-33 to generate central memory immunity, since
    central memory T cells are important subsets of memory CD8
    T cells that also mediate optimal
    protective immunity against pathogens (47,48). Overall, understanding the mechanism of action
    by which IL-33 influences the expansion and development of heterogeneous CD8
    T cell
    populations in vaccines is an important area for further investigation.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.49+0.38(+4.17%)12:38 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.